Impact of capitation on free-standing dialysis facilities: Can you survive?

American Journal of Kidney Diseases

Volumn 30, Issue 4, 1997, Pages 542-548

  McMurray, Stephen D ^a,b   Miller, Jackie ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b Indiana Medical Associates   (United States)

Author keywords

Capitation; Disease management; ESRD; ESRD cost; Hospital cost; Vascular access

Indexed keywords

ADULT; AGED; ARTICLE; CAPITATION FEE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HOSPITAL COST; HUMAN; MALE; MEDICARE; REIMBURSEMENT; VASCULAR ACCESS; VASCULAR SURGERY;

EID: 0030863184     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(97)90314-0     Document Type: Article

References (14)

1. United States Renal Data System: 1996 Annual Report, Executive Summary. Am J Kidney Dis 28:S12-S20, 1996 (suppl 2)
2. Parley DO, Kailich JD, Carter GM, Lucas TW, Spritzer KL: Designing a Capitation Payment Plan for Medicare End Stage Renal Disease Services, Rand/UCLA/Harvard Center for Health Care Financing Policy Research
3. Milliman and Robertson, Special actuarial study courtesy of Baxter Corporation.
4. United States Renal Data Systems: 1996 Annual Report, The Economic Cost of ESRD and Medicare Spending for Alternative Modalities of Treatment. Am J Kidney Dis 28:S127-S140, 1996 (suppl)
5. United States Renal Data Systems: 1995 Annual Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, pp 139-157
6. Tharmer M, Ray NF, Fehrenbach SN, Richard C, Kimmel PL: Relative risk and economic consequences of inpatient care among patients with renal failure. J Am Soc Nephrol 7:751-762, 1996
7. Prowant BF, Kappel DF, Cambell A: A comparison of inpatient and outpatient Medicare allowable charges for continuous ambulatory peritoneal and center hemodialysis patients: A single-center study. Am J Kidney Dis 8:248-252, 1986
8. Teehan BP, Hakim R: Continuous ambulatory peritoneal dialysis: Quo vadis? J Am Soc Nephrol 6:139-142, 1995
9. Muirhead N, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfey P: Evidence based recommendations for the clinical use of recombinant human erythropoetin. Am J Kidney Dis 26:S1-S23, 1995 (suppl 1)
10. Besarab A: Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration. Am J Kidney Dis 22:3-22, 1993 (suppl 1)
11. Fishbane S, Frei G, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
12. Hakim RM, Lazuarus JM: Initiation of dialysis. J Am Soc Nephrol 6:1319-1328, 1995
13. Kallich JD, Litwin MS, Markovich M: Vascular access procedures for end-stage renal disease Medicare beneficiaries. Rand/UCLA/Harvard Center for Policy Research in Health Care Financing
14. Rubin R: Capitation: Will it work for ESRD? Nephrol News Issues 29:38, 1996